These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30514709)

  • 41. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.
    Stahl A; Lepore D; Fielder A; Fleck B; Reynolds JD; Chiang MF; Li J; Liew M; Maier R; Zhu Q; Marlow N
    Lancet; 2019 Oct; 394(10208):1551-1559. PubMed ID: 31522845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II.
    Autrata R; Krejcírová I; Senková K; Holoušová M; Doležel Z; Borek I
    Eur J Ophthalmol; 2012; 22(5):687-94. PubMed ID: 22669848
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spectral-Domain OCT Analyses of Macular Changes After Ranibizumab Therapy for Type 1 Retinopathy of Prematurity.
    Erol MK; Coban DT; Özdemir Ö; Tunay ZÖ; Bilgin AB; Dogan B
    J Pediatr Ophthalmol Strabismus; 2015; 52(3):152-8. PubMed ID: 25859685
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy.
    Kuo HK; Sun IT; Chung MY; Chen YH
    Ophthalmologica; 2015; 234(4):211-7. PubMed ID: 26393895
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ranibizumab in retinopathy of prematurity - one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study.
    Stahl A; Bründer MC; Lagrèze WA; Molnár FE; Barth T; Eter N; Guthoff R; Krohne TU; Pfeil JM;
    Acta Ophthalmol; 2022 Feb; 100(1):e91-e99. PubMed ID: 33742551
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY.
    Harper CA; Wright LM; Young RC; Read SP; Chang EY
    Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity.
    Murakami T; Sugiura Y; Okamoto F; Okamoto Y; Kato A; Hoshi S; Nagafuji M; Miyazono Y; Oshika T
    Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2849-2855. PubMed ID: 33744981
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
    Kim J; Kim SJ; Chang YS; Park WS
    Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.
    Padhi TR; Das T; Kaur P; Sutar S; Khalsa A; Modi R; Ali H; Pradhan L; Jalali S
    Int Ophthalmol; 2020 Apr; 40(4):1007-1015. PubMed ID: 31925658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Refractive error outcomes after intravitreal ranibizumab for retinopathy of prematurity.
    Meng Q; Cheng Y; Wu X; Zhao D; Zhao M; Liang J
    Clin Exp Optom; 2020 Jul; 103(4):495-500. PubMed ID: 31802528
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.
    Menke MN; Framme C; Nelle M; Berger MR; Sturm V; Wolf S
    BMC Ophthalmol; 2015 Mar; 15():20. PubMed ID: 25886603
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aggressive posterior retinopathy of prematurity in two cohorts of patients in South India: implications for primary, secondary, and tertiary prevention.
    Shah PK; Subramanian P; Venkatapathy N; Chan RVP; Chiang MF; Campbell JP
    J AAPOS; 2019 Oct; 23(5):264.e1-264.e4. PubMed ID: 31521847
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY.
    Jin E; Yin H; Li X; Zhao M
    Retina; 2018 Aug; 38(8):1595-1604. PubMed ID: 28699927
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity.
    Cheng Y; Zhu X; Linghu D; Liang J
    Acta Ophthalmol; 2020 Dec; 98(8):e1004-e1008. PubMed ID: 32385940
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FACTORS ASSOCIATED WITH REACTIVATION AFTER INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB THERAPY IN INFANTS WITH RETINOPATHY OF PREMATURITY.
    Iwahashi C; Utamura S; Kuniyoshi K; Sugioka K; Konishi Y; Wada N; Kusaka S
    Retina; 2021 Nov; 41(11):2261-2268. PubMed ID: 33958533
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Five years of treatment for retinopathy of prematurity in Sweden: results from SWEDROP, a national quality register.
    Holmström G; Hellström A; Jakobsson P; Lundgren P; Tornqvist K; Wallin A
    Br J Ophthalmol; 2016 Dec; 100(12):1656-1661. PubMed ID: 26969711
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity.
    Araz-Ersan B; Kir N; Tuncer S; Aydinoglu-Candan O; Yildiz-Inec D; Akdogan B; Ekici B; Demirel A; Ozmen M
    Curr Eye Res; 2015 May; 40(6):585-91. PubMed ID: 25025864
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: A meta-analysis of 3,701 eyes.
    Popovic MM; Nichani P; Muni RH; Mireskandari K; Tehrani NN; Kertes PJ
    Surv Ophthalmol; 2021; 66(4):572-584. PubMed ID: 33338470
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Results of intravitreal ranibizumab treatment for retinopathy of prematurity in infants.
    Sukgen EA; Koçluk Y
    Cutan Ocul Toxicol; 2017 Dec; 36(4):356-361. PubMed ID: 28277877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.